|Awarded On||August 24, 2018|
|Title||Autoimmune-Prone Mouse Models for Studying Immune-Related Adverse Events Associated With Cancer Immunotherapy|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Nan Yan|
|Cancer Sites||All Sites|
*Pending contract negotiation
Recent advance in cancer immunotherapy has demonstrated exciting potential. These drugs that are known as immune checkpoint inhibitors (or ICIs) remove breaks from immune cells and unleash maximum power to attack tumors. Despite tremendous successes with this approach in controlling tumor growth, these unleashed immune cells also attack normal organs resulting in conditions known as immune-related adverse events (or irAEs). The incidence of irAE is reported to range from 15-60% in single drug clinical trails, with even higher occurrence and more severe outcome in combination therapy. irAE affects multiple organs, and in severe cases becoming irreversible and fatal. Poor understanding of irAE...